Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13,643 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Artificial selection for host resistance to tumour growth and subsequent cancer cell adaptations: an evolutionary arms race.
Ibrahim-Hashim A, Luddy K, Abrahams D, Enriquez-Navas P, Damgaci S, Yao J, Chen T, Bui MM, Gillies RJ, O'Farrelly C, Richards CL, Brown JS, Gatenby RA. Ibrahim-Hashim A, et al. Among authors: yao j. Br J Cancer. 2021 Jan;124(2):455-465. doi: 10.1038/s41416-020-01110-1. Epub 2020 Oct 7. Br J Cancer. 2021. PMID: 33024265 Free PMC article.
Targeting the BRD4-HOXB13 Coregulated Transcriptional Networks with Bromodomain-Kinase Inhibitors to Suppress Metastatic Castration-Resistant Prostate Cancer.
Nerlakanti N, Yao J, Nguyen DT, Patel AK, Eroshkin AM, Lawrence HR, Ayaz M, Kuenzi BM, Agarwal N, Chen Y, Gunawan S, Karim RM, Berndt N, Puskas J, Magliocco AM, Coppola D, Dhillon J, Zhang J, Shymalagovindarajan S, Rix U, Kim Y, Perera R, Lawrence NJ, Schonbrunn E, Mahajan K. Nerlakanti N, et al. Among authors: yao j. Mol Cancer Ther. 2018 Dec;17(12):2796-2810. doi: 10.1158/1535-7163.MCT-18-0602. Epub 2018 Sep 21. Mol Cancer Ther. 2018. PMID: 30242092 Free PMC article.
Sirt2 Inhibition Enhances Metabolic Fitness and Effector Functions of Tumor-Reactive T Cells.
Hamaidi I, Zhang L, Kim N, Wang MH, Iclozan C, Fang B, Liu M, Koomen JM, Berglund AE, Yoder SJ, Yao J, Engelman RW, Creelan BC, Conejo-Garcia JR, Antonia SJ, Mulé JJ, Kim S. Hamaidi I, et al. Among authors: yao j. Cell Metab. 2020 Sep 1;32(3):420-436.e12. doi: 10.1016/j.cmet.2020.07.008. Epub 2020 Aug 7. Cell Metab. 2020. PMID: 32768387 Free PMC article.
Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial.
Creelan BC, Wang C, Teer JK, Toloza EM, Yao J, Kim S, Landin AM, Mullinax JE, Saller JJ, Saltos AN, Noyes DR, Montoya LB, Curry W, Pilon-Thomas SA, Chiappori AA, Tanvetyanon T, Kaye FJ, Thompson ZJ, Yoder SJ, Fang B, Koomen JM, Sarnaik AA, Chen DT, Conejo-Garcia JR, Haura EB, Antonia SJ. Creelan BC, et al. Among authors: yao j. Nat Med. 2021 Aug;27(8):1410-1418. doi: 10.1038/s41591-021-01462-y. Epub 2021 Aug 12. Nat Med. 2021. PMID: 34385708 Free PMC article. Clinical Trial.
Differences in the pathological, transcriptomic, and prognostic implications of lymphoid structures between primary and metastatic cutaneous melanomas.
Karapetyan L, Li A, Vargas De Stefano D, Abushukair HM, Al-Bzour AN, Knight A, Layding C, Wang H, Xu J, Yao J, Song X, Joy M, Nguyen J, Moran-Segura C, Bruno S, Sander C, Messina J, Mule JJ, Storkus WJ, Kirkwood JM. Karapetyan L, et al. Among authors: yao j. J Immunother Cancer. 2024 Nov 12;12(11):e009231. doi: 10.1136/jitc-2024-009231. J Immunother Cancer. 2024. PMID: 39537211 Free PMC article.
A Mutational Survey of Acral Nevi.
Smalley KSM, Teer JK, Chen YA, Wu JY, Yao J, Koomen JM, Chen WS, Rodriguez-Waitkus P, Karreth FA, Messina JL. Smalley KSM, et al. Among authors: yao j. JAMA Dermatol. 2021 Jul 1;157(7):831-835. doi: 10.1001/jamadermatol.2021.0793. JAMA Dermatol. 2021. PMID: 33978681 Free PMC article.
13,643 results
You have reached the last available page of results. Please see the User Guide for more information.